The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis
To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD).
Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Antidepressants are recommended for use in the treatment of moderate-to-severe major depression [1], but many patients fail to benefit from these medications. Between 30 and 50% of patients with major depressive disorder (MDD) do not respond to their first antidepressant trial [2] and remission rates are as low as 37.5% [3].
Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review
Major depressive disorder (MDD) is one of the most prevalent mood disorders worldwide. The World Health Organization (WHO) reports that more than 300 million people from all age groups are affected by depression worldwide.1 Globally, depression is considered one of the major causes of disability
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective
Depression is a significant health and economic burden in Canada. In addition to the impact of depression on patients’ health and quality of life [1], it costs the Canadian economy more than CAD $32 billion annually [2].The cost of depression stems directly from increased healthcare resource utilization and indirectly as a result of increased disability and absenteeism [3,4]. For example, the direct and indirect per-patient costs were 3.5 and three-times higher, respectively,
Pharmacogenetics in Psychiatry: An Update on Clinical Usability
Using pharmacogenetics in guiding drug therapy experiences a steady increase in uptake, although still leads to discussions as to its clinical use. Psychiatry constitutes a field where pharmacogenomic testing might help in guiding drug therapy.
Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression
Predictors of treatment outcome in major depressive disorder (MDD) could contribute to evidence-based therapeutic choices. Combined pharmacotherapy and psychotherapy show increased efficacy but higher cost compared with antidepressant pharmacotherapy.
Assessment of an automated approach for variant interpretation in screening for monogenic disorders: A single-center study
Automation has been introduced into variant interpretation, but it is not known how automated variant interpretation performs on a stand- alone basis. The purpose of this study was to evaluate a fully automated computerized approach.
The association of HBB-related significant hemoglobinopathies and low fetal fraction on noninvasive prenatal screening for fetal aneuploidy
HBB-related significant hemoglobinopathies have been anecdotally associated with low fetal fraction on noninvasive prenatal screening (NIPS). We sought to compare the difference in fetal fraction using NIPS in women with HBB-related significant hemoglobinopathies (HSH) and women with normal hemoglobin.
Reproductive Carrier Screening Results With Maternal Health Implications During Pregnancy
Single gene (monogenic) disorders are a leading cause of morbidity and mortality in newborn and pediatric populations. In the North American population, the incidence of monogenic heritable disease is at least 3.6 of 1,000 births.1,2 Offering prepregnancy or prenatal carrier screening for monogenic disorders with moderate to severe phenotypes
Worldwide live births following the transfer of chromosomally “Abnormal” embryos after PGT/A: results of a worldwide web-based survey
In July 2016, the International Preimplantation Diagnosis International Society (PGDIS) modified reporting guidelines for what until then was called preimplantation genetic screening (PGS), and for the first time allowed selective transfers of